Effect of Buprenorphine Dose on Treatment Outcome

Fareed, Ayman; Vayalapalli, Sreedevi; Casarella, Jennifer; Drexler, Karen

doi:10.1080/10550887.2011.642758

Cited by 116 publications

(87 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Neither the main effect of day 30 dose nor the interaction effect of day 30 dose and emerging adult age status were significant when added to all of these models with emerging adult age status. A recent meta-analysis reported that higher prescribed buprenorphine dosage was associated with increased retention and less illicit opioid use among adults of all ages (Fareed, Vayalapalli, Casarella, & Drexler, 2012). In contrast, higher day 30 dose levels among emerging adults in this study were paradoxically associated with increased rates of positive toxicology for illicit opioids in the second month of treatment ( p < 0.05).…”

Section: Resultsmentioning

confidence: 99%

Emerging adult age status predicts poor buprenorphine treatment retention

Schuman‐Olivier

Weiss

Hoeppner

et al. 2014

Journal of Substance Abuse Treatment

101

View full text Add to dashboard Cite

Emerging adults (18–25 years old) are often poorly retained in substance use disorder treatment. Office-based buprenorphine often enhances treatment retention among people with opioid dependence. In this study, we examined the records of a collaborative care buprenorphine treatment program to compare the treatment retention rates of emerging adults versus older adults. Subjects were 294 adults, 71 (24%) aged 18–25, followed in treatment with buprenorphine, nurse care management, and an intensive outpatient program followed by weekly psychosocial treatment. Compared to older adults, emerging adults remained in treatment at a significantly lower rate at 3 months (56% versus 78%) and 12 months (17% versus 45%), and were significantly more likely to test positive for illicit opioids, relapse, or drop out of treatment. Further research into factors associated with buprenorphine treatment retention among emerging adults is needed to improve treatment and long-term outcomes in this group.

show abstract

Section: Resultsmentioning

confidence: 99%

Emerging adult age status predicts poor buprenorphine treatment retention

Schuman‐Olivier

Weiss

Hoeppner

et al. 2014

Journal of Substance Abuse Treatment

101

View full text Add to dashboard Cite

show abstract

“…This suggests that clinicians using standard opioid conversion calculations (Fine, Portenoy, et al 2009) are at risk of underestimating the buprenorphine-naloxone dose that codeine dependent users actually require resulting in poorer clinical outcomes, and also, suggesting that high doses of buprenorphine-naloxone (up to 32mg daily) appears safe and well tolerated by this group of codeine dependent users (Nielsen et al 2015b). While individual dose titration is best practice (Gowing, Ali, Dunlop, Farrell, and Lintzeris 2014) a recommendation that codeine dependent individuals receive similar doses to that of other opioid dependents is suggested (Nielsen, Hillhouse, Mooney, Fahey, and Ling 2012), thereby improving treatment retention (Fareed, Vayalapalli, Casarella, and Drexler 2012).…”

Section: Discussionmentioning

confidence: 99%

Buprenorphine-Naloxone in the Treatment of Codeine Dependence: a Scoping Review of Clinical Case Presentations

Hout

Hearne

Bergin

2016

Int J Ment Health Addiction

View full text Add to dashboard Cite

show abstract

“…1 Several studies reported that buprenorphine is a safe and effective medication for treatment of opioid dependence in both the inpatient and outpatient setting. [2][3][4][5][6] It has several pharmacological properties that make it particularly advantageous in the outpatient setting, where the safety profile of a medication is of great concern.…”

mentioning

confidence: 99%